Pacira Pharmaceuticals (Nasdaq: PCRX) reported earnings on Aug. 9. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended June 30 (Q2), Pacira Pharmaceuticals crushed expectations on revenue and exceeded expectations on earnings per share.

Compared to the prior-year quarter, revenue improved significantly and GAAP loss per share dropped.

Margins increased across the board.

Revenue details
Pacira Pharmaceuticals logged revenue of $12.3 million. The four analysts polled by S&P Capital IQ anticipated revenue of $8.8 million on the same basis. GAAP reported sales were much higher than the prior-year quarter's $3.6 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
EPS came in at -$0.27. The three earnings estimates compiled by S&P Capital IQ anticipated -$0.52 per share. GAAP EPS were -$0.27 for Q2 against -$0.51 per share for the prior-year quarter.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
For the quarter, gross margin was 45.8%, 3,150 basis points better than the prior-year quarter. Operating margin was -53.7%, 18,090 basis points better than the prior-year quarter. Net margin was -67.2%, 17,380 basis points better than the prior-year quarter.

Looking ahead
Next quarter's average estimate for revenue is $9.4 million. On the bottom line, the average EPS estimate is -$0.34.

Next year's average estimate for revenue is $42.5 million. The average EPS estimate is -$1.49.

Investor sentiment
The stock has a one-star rating (out of five) at Motley Fool CAPS, with 17 members out of 26 rating the stock outperform, and nine members rating it underperform. Among nine CAPS All-Star picks (recommendations by the highest-ranked CAPS members), four give Pacira Pharmaceuticals a green thumbs-up, and five give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Pacira Pharmaceuticals is buy, with an average price target of $16.60.